Purpose of the study
It is not fully elucidated whether patients who receive combination antiretroviral therapy (cART) can maintain continued CD4+ T-cell count increases. Previous studies suggested a plateau 2-4 years after treatment initiation. We aimed to characterize the evolution of CD4+ T-cell count in HIV-infected individuals receiving long-term suppressive cART.
Methods
This is a retrospective study of patients receiving cART in an HIV clinic cohort that maintained viral suppression (HIV-RNA <400 copies/mL) for ≥5 years. We used linear regression models to determine for each individual whether CD4+ T-cell count continued to increase. Furthermore, we estimated whether the slope of CD4+ T-cell count for each individual became zero which we defined as the CD4+ set-point. Using logistic regression methods, we assessed factors associated with continued CD4+ T-cell count rise and CD4+ set-point.
Summary of results
59 patients were included. The median baseline CD4+ Tcell count was 238 (IQR, 120-360) cells/μL and the median duration on ART was 7.6 (IQR, 5.9-9.3) years. Independent predictors of continued CD4+ T-cell count increase were baseline log10 HIV-RNA (OR 0.35, 95% CI 0.14-0.89; p = 0.026) and duration on ART (OR 0.65, 95% CI 0.47-0.91; p = 0.021). The CD4+ T-cell percentage at the start of ART was a significant predictor of time to the CD4+ set point (HR 2.4, 95% CI 1.3-4.5; p < 0.01). Patients who reached a CD4+ set-point had a significantly higher baseline CD4+ T-cell percentage at the start of ART compared to those who did not reach a CD4+ set-point; 
Conclusion
These findings suggest that CD4+ T-cell count continues to increase in some patients after several years of cART. Our results point to an advantage to commencing cART at higher CD4+ T-cell strata.
